Analysts expect India's Dr Reddy's Q4 profit to rise 29%
** Shares of generic drugmaker Dr Reddy's REDY.NS down ~1% at 6,241.60 rupees
** Analysts on avg expect REDY's Q4 consol net PAT to rise 29% and rev to grow 13%, per LSEG, vs 11% climb in its Q3 profit and 7% rev growth
** Jefferies analysts expect REDY, rivals Cipla CIPL.NS and Zydus Lifescience ZYDU.NS to benefit from strong sales of gRevlimid; expect benign price environment to continue in the U.S., the biggest market for these drugmakers
** Centrum analysts expect increased traction in limited competition products such as gRevlimid to boost U.S. generics business
** Avg rating of analysts on REDY at "Hold", while rivals CIPL and Sun Pharma SUN.NS rated "Buy" - LSEG data
** Cipla to report Q4 results on Friday
** REDY's 6.2% climb in Q4 smallest vs CIPL's 20% rise and SUN's 29%; Nifty pharma index .NIPHARM gained 13%
Reporting by Kashish Tandon in Bengaluru
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
